Common Contracts
2 similar Development and License Agreement contracts
Amendment date: Jul 06 2015Development and License Agreement • December 26th, 2022 • New York
Novo Nordisk is terminating its 18 month partnership with Zosano Pharma to use that company’s micro-needle application to deliver glucagon-like peptide-1 (GLP-1) analogues for the treatment of type 2 diabetes.
Amendment date: Jul 06 2015Development and License Agreement • November 29th, 2022 • New York
Novo Nordisk is terminating its 18 month partnership with Zosano Pharma to use that company’s micro-needle application to deliver glucagon-like peptide-1 (GLP-1) analogues for the treatment of type 2 diabetes.
